# PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata

> **NCT01629563** · PHASE3 · COMPLETED · sponsor: **PregLem SA** · enrollment: 451 (actual)

## Conditions studied

- Uterine Fibroids

## Interventions

- **DRUG:** PGL4001 5 mg
- **DRUG:** PGL4001 10 mg

## Key facts

- **NCT ID:** NCT01629563
- **Lead sponsor:** PregLem SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06
- **Primary completion:** 2015-01
- **Final completion:** 2015-01
- **Target enrollment:** 451 (ACTUAL)
- **Last updated:** 2019-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01629563

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01629563, "PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01629563. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*